Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 8/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 4/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21758696 | 0.95 | CYP11B2 (0.38) | CYP11B2CYP11B1CYP17A1FLT3NEK1 | |
| SCHEMBL21758169 | 0.94 | CYP11B2 (0.36) | CYP11B2CYP11B1CYP17A1FLT3PTGER4 | |
| SCHEMBL21758324 | 0.94 | NEK1 (0.40) | CYP11B2CYP11B1CYP17A1FLT3PTGER4 | |
| SCHEMBL21758316 | 0.94 | CYP11B2 (0.39) | CYP11B2CYP11B1CYP17A1FLT3PTGER4 | |
| SCHEMBL21758164 | 0.93 | CYP11B2 (0.36) | CYP11B2CYP11B1CYP17A1FLT3PTGER4 | |
| SCHEMBL21758152 | 0.93 | CYP11B2 (0.39) | CYP11B2CYP11B1CYP17A1FLT3PTGER4 | |
| SCHEMBL21758693 | 0.91 | PTGER4 (0.37) | CYP11B2CYP11B1CYP17A1FLT3PTGER4 | |
| SCHEMBL23347903 | 0.89 | CYP1A2 (0.37) | CYP11B2CYP11B1CYP17A1FLT3NEK1 | |
| SCHEMBL21758151 | 0.89 | CYP11B2 (0.41) | CYP11B2CYP11B1CYP17A1FLT3NEK1 | |
| SCHEMBL21758320 | 0.89 | NEK1 (0.43) | CYP11B2CYP11B1CYP17A1FLT3NEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3638749-B1 | ORGANIC MOLECULE, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-05-19 | — | — | EP | disclosed |
| US-20200062734-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062734-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | OXER1, OR10J3, OXGR1 | CYP11B2 1243/4885CYP11B1 1224/4885CYP17A1 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.